2019 Analytical Report for Healthcare Licensing with Focus on Biomarkers - ResearchAndMarkets.com

DUBLIN--()--The "Analytical Report for Healthcare Licensing with focus on Biomarkers" report has been added to ResearchAndMarkets.com's offering.

Biomarker research has become an important component of the drug discovery and development process. Moreover, with the growing trend in personalized medicine and companion diagnostics, the use of biomarkers is becoming obligatory in the management of certain diseases. An in-depth update on its licensing trends is presented in this report. 50+ licensing news with a focus on Biomarkers, during January 1, 2018, to July 31, 2019, are reported and analyzed to provide a snapshot view of the current business trends.

Analytical data coverage:

  • January 1, 2018, to July 31, 2019, licensing deals and negotiations
  • 160+ worldwide Biomarkers focused healthcare licensing news of companies across North America (58%), Europe (30%), Asia (9%)
  • Small-mid-large cap companies covered - Large-Cap (11%)
  • Listed and non-listed companies included
  • 4 healthcare sub-sectors covered - Pharmaceuticals (13%), Biotech (38%), Healthcare Services (33%), Medical Devices (16%)
  • 14 medicine groups studied - Oncology (43%), Neurology (15%)
  • 8+ variables analyzed

User benefits:

  • Immediate access to current global licensing trends for Biomarkers
  • Succinct summaries of licensing deals and negotiations held worldwide
  • Quick to-the-point analytical references
  • In-depth updates on the wider perspective of Biomarkers
  • Directions to the emerging business prospects

Key Topics Covered:

Introduction

Research Design

Chapter 1: Analysis of healthcare inventions with focus on Biomarkers licensed during the past 19 months

1.1 Number of licensing deals with a focus on Biomarkers

1.2 Countries with most licensing deals with a focus on Biomarkers

1.3 Healthcare sub-sectors with most licensing deals with a focus on Biomarkers

1.4 Market capitalization groups with most licensing deals with a focus on Biomarkers

1.5 Medicine groups with most licensing deals with a focus on Biomarkers

1.6 Leading companies with most licensing deals with a focus on Biomarkers

1.7 Licensing payment arrangements most followed in licensing deals with a focus on Biomarkers

Chapter 2: Key licensing deals with a focus on Biomarkers during the past 19 months - By type of licensing deal

Chapter 3: Global healthcare inventions with focus on Biomarkers licensed during the past 19 months - By region and company name

Chapter 4: Summary and conclusions

Appendices

Appendix 1 List of companies/institutes covered

a) By region, country and company name

b) By sub-industry, country and company name

c) By market capitalization group, country and company name

d) By medicine group, country and company name

e) By terms of payment, country and company name

Appendix 2 List of non-listed companies covered - By country and company name

Appendix 3 List of not-for-profit institutes covered - By country and institute name

For more information about this report visit https://www.researchandmarkets.com/r/ewiptr

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900